Bundeswehrkrankenhaus Ulm
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
At Bundeswehrkrankenhaus Ulm, research in hematologic diseases focuses on improving care for patients with aggressive blood cancers, especially high-risk large B-cell lymphoma and multiple myeloma. These studies are designed to evaluate whether new treatment combinations can strengthen disease control and deepen responses in newly diagnosed or previously untreated patients.
- Testing new treatment combinations for high-risk large B-cell lymphoma
- Studying strategies to improve outcomes in multiple myeloma
- Assessing whether treatment approaches can increase remission quality and delay progression
The work at this site aims to refine treatment effectiveness in complex blood cancers while supporting better long-term disease management.
Neoplasms
Clinical trials in neoplasms at this hospital center on advanced cancers, with a strong emphasis on non-small cell lung cancer and metastatic disease. The research is exploring new therapy combinations to improve survival, slow cancer growth, and expand options for patients with difficult-to-treat tumors.
- Evaluating new treatments for advanced non-small cell lung cancer
- Studying approaches for locally advanced or metastatic NSCLC
- Assessing whether added therapies improve progression-free survival and overall survival
Several studies are also examining whether targeted and immune-based combinations can offer added benefit in patients with specific tumor features, including KRAS G12C mutation and PD-L1 expression.
Respiratory Tract Diseases
Research in respiratory tract diseases at Bundeswehrkrankenhaus Ulm is concentrated on lung cancer, especially stage IV, recurrent, and non-squamous non-small cell lung cancer. The trials are aimed at testing whether newer treatment regimens can improve survival and disease control for people with advanced lung disease.
- Investigating therapies for stage IV or recurrent non-small cell lung cancer
- Comparing treatment options for non-squamous NSCLC
- Exploring whether novel combinations can extend overall survival
This respiratory oncology research reflects a broader effort to improve outcomes for patients with advanced lung cancer through more effective and personalized treatment strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Bundeswehrkrankenhaus Ulm
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion | Bristol-Myers Squibb Services Unlimited Company | Phase IV | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 4 | Unknown | 2021-03-17 | 2025-11-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.